Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data

Jae Hoon Lee, Jae Yen Song, Kyong Wook Yi, Sa Ra Lee, Dong Yun Lee, Jung-Ho Shin, Si Hyun Cho, Seok Kyo Seo, Sung Hoon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment (P for trend <.001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks (P for trend =.0288). Overall, 51 (42.15%) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75%, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis.

Original languageEnglish
Pages (from-to)1515-1522
Number of pages8
JournalReproductive Sciences
Volume25
Issue number10
DOIs
Publication statusPublished - 2018 Oct 1

Fingerprint

dienogest
Endometriosis
Antigens
Pain
Neoplasms

Keywords

  • dienogest
  • endometrioma
  • endometriosis
  • recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Effectiveness of Dienogest for Treatment of Recurrent Endometriosis : Multicenter Data. / Lee, Jae Hoon; Song, Jae Yen; Yi, Kyong Wook; Lee, Sa Ra; Lee, Dong Yun; Shin, Jung-Ho; Cho, Si Hyun; Seo, Seok Kyo; Kim, Sung Hoon.

In: Reproductive Sciences, Vol. 25, No. 10, 01.10.2018, p. 1515-1522.

Research output: Contribution to journalArticle

Lee, Jae Hoon ; Song, Jae Yen ; Yi, Kyong Wook ; Lee, Sa Ra ; Lee, Dong Yun ; Shin, Jung-Ho ; Cho, Si Hyun ; Seo, Seok Kyo ; Kim, Sung Hoon. / Effectiveness of Dienogest for Treatment of Recurrent Endometriosis : Multicenter Data. In: Reproductive Sciences. 2018 ; Vol. 25, No. 10. pp. 1515-1522.
@article{0e2bbcc2d3ff4a8faf054ddb91515412,
title = "Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data",
abstract = "This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment (P for trend <.001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks (P for trend =.0288). Overall, 51 (42.15{\%}) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75{\%}, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis.",
keywords = "dienogest, endometrioma, endometriosis, recurrence",
author = "Lee, {Jae Hoon} and Song, {Jae Yen} and Yi, {Kyong Wook} and Lee, {Sa Ra} and Lee, {Dong Yun} and Jung-Ho Shin and Cho, {Si Hyun} and Seo, {Seok Kyo} and Kim, {Sung Hoon}",
year = "2018",
month = "10",
day = "1",
doi = "10.1177/1933719118779733",
language = "English",
volume = "25",
pages = "1515--1522",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "10",

}

TY - JOUR

T1 - Effectiveness of Dienogest for Treatment of Recurrent Endometriosis

T2 - Multicenter Data

AU - Lee, Jae Hoon

AU - Song, Jae Yen

AU - Yi, Kyong Wook

AU - Lee, Sa Ra

AU - Lee, Dong Yun

AU - Shin, Jung-Ho

AU - Cho, Si Hyun

AU - Seo, Seok Kyo

AU - Kim, Sung Hoon

PY - 2018/10/1

Y1 - 2018/10/1

N2 - This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment (P for trend <.001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks (P for trend =.0288). Overall, 51 (42.15%) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75%, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis.

AB - This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment (P for trend <.001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks (P for trend =.0288). Overall, 51 (42.15%) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75%, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis.

KW - dienogest

KW - endometrioma

KW - endometriosis

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85047896954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047896954&partnerID=8YFLogxK

U2 - 10.1177/1933719118779733

DO - 10.1177/1933719118779733

M3 - Article

C2 - 29848190

AN - SCOPUS:85047896954

VL - 25

SP - 1515

EP - 1522

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 10

ER -